KR20250107210A - 이부타모렌의 압축형 경구 제형 - Google Patents

이부타모렌의 압축형 경구 제형 Download PDF

Info

Publication number
KR20250107210A
KR20250107210A KR1020257018282A KR20257018282A KR20250107210A KR 20250107210 A KR20250107210 A KR 20250107210A KR 1020257018282 A KR1020257018282 A KR 1020257018282A KR 20257018282 A KR20257018282 A KR 20257018282A KR 20250107210 A KR20250107210 A KR 20250107210A
Authority
KR
South Korea
Prior art keywords
day
solid dosage
dosage form
tablet
pharmaceutical solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257018282A
Other languages
English (en)
Korean (ko)
Inventor
알파 비. 파리크
존 씨. 맥큐
Original Assignee
루모스 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루모스 파마, 인크. filed Critical 루모스 파마, 인크.
Publication of KR20250107210A publication Critical patent/KR20250107210A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020257018282A 2022-11-03 2022-11-22 이부타모렌의 압축형 경구 제형 Pending KR20250107210A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263422329P 2022-11-03 2022-11-03
US63/422,329 2022-11-03
PCT/US2022/050700 WO2024096892A1 (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Publications (1)

Publication Number Publication Date
KR20250107210A true KR20250107210A (ko) 2025-07-11

Family

ID=90835855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257018282A Pending KR20250107210A (ko) 2022-11-03 2022-11-22 이부타모렌의 압축형 경구 제형

Country Status (12)

Country Link
US (2) US11969416B1 (https=)
EP (1) EP4611737A1 (https=)
JP (2) JP2025535941A (https=)
KR (1) KR20250107210A (https=)
CN (1) CN120239602A (https=)
AU (1) AU2022485048A1 (https=)
CL (1) CL2025001309A1 (https=)
CO (1) CO2025007025A2 (https=)
GE (1) GEAP202516774A (https=)
IL (1) IL320529A (https=)
MX (1) MX2025005154A (https=)
WO (1) WO2024096892A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
AU7522896A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
BR0113626A (pt) * 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
EP2001475B1 (en) 2006-03-15 2018-11-14 Michael O. Thorner Methods for treating sarcopenia with a growth hormone secretagogue
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
BR112015022398B1 (pt) * 2013-03-14 2022-01-11 Redhill Biopharma Ltd Comprimido de ondansetrona e preparação farmacêutica embalada
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
AU2016328969B2 (en) 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Also Published As

Publication number Publication date
EP4611737A1 (en) 2025-09-10
JP2025535941A (ja) 2025-10-30
GEAP202516774A (en) 2025-06-25
CL2025001309A1 (es) 2025-09-26
WO2024096892A1 (en) 2024-05-10
CO2025007025A2 (es) 2025-07-17
JP2026027432A (ja) 2026-02-18
CN120239602A (zh) 2025-07-01
US20240245663A1 (en) 2024-07-25
IL320529A (en) 2025-06-01
MX2025005154A (es) 2025-07-01
US11969416B1 (en) 2024-04-30
US20240156793A1 (en) 2024-05-16
AU2022485048A1 (en) 2025-05-22
US12390452B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
EP3302565B1 (en) Solid dosage forms of palbociclib
EP2510950B1 (en) Dry-coated orally disintegrating tablet
JP7254871B2 (ja) 口腔内崩壊錠
KR101667081B1 (ko) 이르베사르탄 및 암로디핀을 포함하는 고형의 고정 용량 제약 조성물, 그의 제법 및 그의 치료학적 용도
RU2333757C2 (ru) Фармацевтические композиции
CN116159052B (zh) 联合用药应用以及一种药用组合物及其应用
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
JP2026027432A (ja) イブタモレンの圧縮型経口製剤
EP4045048A1 (en) Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
US20160256454A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
JP3884056B1 (ja) 口腔内速崩錠の製造方法
WO2022228735A1 (en) Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
CN101208085B (zh) 1-[(3-羟基-金刚烷基-1-基氨基)-乙酰基]-吡咯烷基-2(s)-腈的调释制剂
US20160022661A1 (en) Dosage Form Comprising Crizotinib
CN115835859A (zh) 包括西他列汀和达格列净的复合制剂以及其制备方法
US20250332149A1 (en) Piperidine compounds and pharmaceutical compositions
EP4431088A1 (en) Pharmaceutical compositions comprising dapagliflozin and metformin
US20260041641A1 (en) Novel formulation
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
EP4512392A2 (en) Orally-administered preparation containing solifenacin and tamsulosin
RU2773029C2 (ru) Галеновые композиции органических соединений
JP2002512614A (ja) 化学的かつ熱的に安定なノルアステミゾール製剤
EP4427742A1 (en) Pharmaceutical compositions comprising dapagliflozin and metformin
CN1476841A (zh) 葛根素分散片组合物及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000